Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 3;23(1):514.
doi: 10.3390/ijms23010514.

Acute Myeloid Leukemia-Related Proteins Modified by Ubiquitin and Ubiquitin-like Proteins

Affiliations
Review

Acute Myeloid Leukemia-Related Proteins Modified by Ubiquitin and Ubiquitin-like Proteins

Sang-Soo Park et al. Int J Mol Sci. .

Abstract

Acute myeloid leukemia (AML), the most common form of an acute leukemia, is a malignant disorder of stem cell precursors of the myeloid lineage. Ubiquitination is one of the post-translational modifications (PTMs), and the ubiquitin-like proteins (Ubls; SUMO, NEDD8, and ISG15) play a critical role in various cellular processes, including autophagy, cell-cycle control, DNA repair, signal transduction, and transcription. Also, the importance of Ubls in AML is increasing, with the growing research defining the effect of Ubls in AML. Numerous studies have actively reported that AML-related mutated proteins are linked to Ub and Ubls. The current review discusses the roles of proteins associated with protein ubiquitination, modifications by Ubls in AML, and substrates that can be applied for therapeutic targets in AML.

Keywords: ISGylation; NEDDylation; SUMOylation; deubiquitination; ubiquitination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
An enzymatic cascade of Ub and Ubls, and deconjugating enzymes. Ub and Ubls are conjugated to target substrates by an enzymatic cascade involving E1, E2, and E3. A modifier is first activated by an E1 activating enzyme and is transferred onto an E2 conjugating enzyme. Subsequently, E3 ligase interacts simultaneously with a modifier-loaded E2 and the target protein, and induces an isopeptide bond between the C-terminus of modifier and a lysine residue of the substrate. Once a modifier is conjugated to their targets, polypeptide chains are formed due to the presence of suitable motifs on modifiers. Deconjugating enzymes are responsible for the reverse process of the modification.
Figure 2
Figure 2
Schematic diagram of the FLT3-ITD signaling pathway. c-Cbl ubiquitinates and induces proteasomal degradation of FLT3-ITD, whereas c-Cbl mutant (R420Q) could not ubiquitinate. USP9X and USP10 deubiquitinate and increase the stability of FLT3-ITD.
Figure 3
Figure 3
Schematic diagram of the C/EBPα signaling pathway. TRIB1 binds to COP1 and enhances its ubiquitin ligase activity. COP1 and SCFSkp2 ubiquitinate and induce proteasomal degradation of FLT3-ITD. TRIB2 binds and promotes proteasome-dependent C/EBPα degradation.

Similar articles

Cited by

References

    1. Lowenberg B., Rowe J.M. Introduction to the review series on advances in acute myeloid leukemia (AML) Blood. 2016;127:1. doi: 10.1182/blood-2015-10-662684. - DOI - PubMed
    1. Juliusson G., Hough R. Leukemia. Prog. Tumor. Res. 2016;43:87–100. - PubMed
    1. Nishikata I., Sasaki H., Iga M., Tateno Y., Imayoshi S., Asou N., Nakamura T., Morishita K. A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. Blood. 2003;102:3323–3332. doi: 10.1182/blood-2002-12-3944. - DOI - PubMed
    1. Horibata S., Gui G., Lack J., DeStefano C.B., Gottesman M.M., Hourigan C.S. Heterogeneity in refractory acute myeloid leukemia. Proc. Natl. Acad. Sci. USA. 2019;116:10494–10503. doi: 10.1073/pnas.1902375116. - DOI - PMC - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed